Can Repligen (RGEN) Stay Undervalued On Russell Index Removals And Margin Concerns?
Index removals put Repligen in focus
Repligen (RGEN) has drawn fresh attention after being dropped from multiple Russell growth and small cap benchmarks, a shift that raises questions about how index changes and existing business pressures intersect for the stock.
See our latest analysis for Repligen.
Repligen’s recent index removals come after a mixed run in the stock, with a 1 month share price return of 10.61% and a 90 day share price return of 19.85%. However, the year to date share price has declined 12.42%, while the 1 year total shareholder return is 7.42% and the 5 year total shareholder return is down 26.97%. This suggests that near term momentum has picked up even as longer term returns remain under pressure.
If you are reassessing your exposure to bioprocessing and healthcare tools, it can be useful to see what else is moving in related areas through 40 healthcare AI stocks
Repligen now trades at $143.94, sitting between a 23% discount to analyst targets and a smaller implied discount to intrinsic value. Where in that spread does a reasonable fair value case actually land?
Most Popular Narrative: 18.3% Undervalued
Against the current Repligen share price of $143.94, the most followed narrative puts fair value at $176.11. This frames the stock as meaningfully undervalued based on its projected earnings and cash flows under an 8.07% discount rate.
Strong and sustained order growth across biopharma, CDMO, and capital equipment segments, supported by record multi quarter book to bill ratios and a robust funnel, positions the company for above market revenue increases as therapy pipelines expand and demand for advanced bioprocessing solutions rises. Despite muted new modality growth, strength in monoclonal antibodies and broader commercial wins plus operating expense discipline are allowing for operating leverage, putting the company on track for consistent net earnings and EBITDA margin expansion.
Want to see what sits behind that growth story for Repligen? The narrative hinges on compounding revenue, higher margins and a rich future earnings multiple that might surprise you.
Result: Fair Value of $176.11 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Repligen’s story could shift quickly if funding for smaller biotech customers stays weak or if exposure to gene therapy and AAV continues to affect revenue mix and margins.
Find out about the key risks to this Repligen narrative.
Another View on Repligen’s valuation
While the prevailing Repligen narrative leans on earnings growth and fair value at $176.11, the market’s own pricing sends a different signal. At a P/S of 10.6x versus an industry average of 3.9x and a fair ratio of 5.5x, investors are paying a hefty premium. Is that gap justified by the story, or is it valuation risk in plain sight?
To see how that premium stacks up across peers and where the fair ratio suggests the market could move, take a closer look at the detailed valuation work in See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Are you cautious or optimistic after reviewing Repligen’s recent moves? With both risks and rewards in play, consider reviewing the 4 key rewards and 1 important warning sign soon.
Looking for more investment ideas beyond Repligen?
If Repligen has sharpened your focus, now is a good time to widen your watchlist with other stock ideas that fit clear, data driven criteria.
- Spot potential value opportunities before the crowd by checking stocks highlighted in the 44 high quality undervalued stocks.
- Strengthen the defensive side of your portfolio by focusing on companies featured in the 73 resilient stocks with low risk scores.
- Hunt for lesser known opportunities with solid fundamentals using the screener containing 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com